Literature DB >> 27282449

Prognostic value of post-treatment metabolic tumor volume from 11C-methionine PET/CT in recurrent malignant glioma.

Tae-Young Jung1, Jung-Joon Min2, Hee-Seung Bom2, Shin Jung1, In-Young Kim1, Sa-Hoe Lim1, Dong-Yeon Kim2, Seong Young Kwon3.   

Abstract

We investigated the diagnostic and prognostic significance of metabolic parameters from 11C-methionine (MET) positron emission tomography (PET) in patients with malignant glioma. The MET-PET was examined in 42 patients who had been previously treated with adjuvant treatment for malignant glioma. Both ratios of maximal MET uptake of the tumors to those of the contralateral normal gray matter (T/N ratio) and metabolic tumor volume (MTV) were estimated in each lesion. The diagnostic performance for recurrence was investigated in all enrolled patients. A definitive diagnosis was done with pathologic confirmation or clinical follow-up. Among recurrent patients, we evaluated the prognostic value of metabolic parameters (T/N ratio and MTV) as well as clinical factors. Among 42 patients, 35 patients were revealed with recurrence. Both T/N ratios (p = 0.009) and MTV (p = 0.001) exhibited statistical significance to differentiate between recurrence and post-treatment radiation effect. A T/N ratio of 1.43 provided the best sensitivity and specificity for recurrence (91.4 and 100 %, respectively), and a MTV of 6.72 cm3 provided the best sensitivity and specificity (77.1 % and 100 %, respectively). To evaluate the prognostic impact, different cutoffs of MTV were examined in patients with recurrent tumor and a threshold of 60 cm3 was determined as a best cutoff value to separate the patients in two prognostic groups. Univariate analysis revealed improved overall survival (OS) for patients with Karnofsky performance scale (KPS) score ≥70 (p < 0.001) or MTV <60 cm3 (p = 0.049). Multivariate analysis showed that patients with KPS score ≥70 (p < 0.001; hazard ratio = 0.104; 95 % CI, 0.029-0.371) or MTV < 60 cm3 (p = 0.031; hazard ratio = 0.288; 95 % CI, 0.093-0.895) were significantly associated with a longer OS. However, T/N ratio was not correlated with patients' outcome. Metabolic parameters had the diagnostic value to differentiate recurrence from post-treatment radiation effect. Compared with T/N ratio, MTV was an independent significant prognostic factor with KPS score in patients with recurrent tumor. Our study had a potential to manage these patients according to prognostic information using MET-PET.

Entities:  

Keywords:  11C-methionine; Metabolic tumor volume; PET; Prognosis; Recurrence

Mesh:

Substances:

Year:  2016        PMID: 27282449     DOI: 10.1007/s10143-016-0748-1

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  21 in total

1.  Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions.

Authors:  Shozo Okamoto; Tohru Shiga; Naoya Hattori; Naoki Kubo; Toshiki Takei; Norio Katoh; Yutaka Sawamura; Kenichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Ann Nucl Med       Date:  2010-12-28       Impact factor: 2.668

2.  Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Authors:  Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

Review 4.  Value of 11C-methionine PET in imaging brain tumours and metastases.

Authors:  Andor W J M Glaudemans; Roelien H Enting; Mart A A M Heesters; Rudi A J O Dierckx; Ronald W J van Rheenen; Annemiek M E Walenkamp; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

5.  Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography.

Authors:  Natsuki Shinozaki; Yoshio Uchino; Kyosan Yoshikawa; Tomoo Matsutani; Azusa Hasegawa; Naokatsu Saeki; Yasuo Iwadate
Journal:  J Neurosurg       Date:  2011-01-07       Impact factor: 5.115

6.  Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas.

Authors:  Kenji Torii; Naohiro Tsuyuguchi; Joji Kawabe; Ichiro Sunada; Mitsuhiro Hara; Susumu Shiomi
Journal:  Ann Nucl Med       Date:  2005-12       Impact factor: 2.668

7.  Usefulness of L-[methyl-11C] methionine-positron emission tomography as a biological monitoring tool in the treatment of glioma.

Authors:  Tadashi Nariai; Yoji Tanaka; Hiroaki Wakimoto; Masaru Aoyagi; Masashi Tamaki; Kiichi Ishiwata; Michio Senda; Kenji Ishii; Kimiyoshi Hirakawa; Kikuo Ohno
Journal:  J Neurosurg       Date:  2005-09       Impact factor: 5.115

8.  Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity.

Authors:  T Kato; J Shinoda; N Oka; K Miwa; N Nakayama; H Yano; T Maruyama; Y Muragaki; T Iwama
Journal:  AJNR Am J Neuroradiol       Date:  2008-08-07       Impact factor: 3.825

9.  Volumetry of [¹¹C]-methionine positron emission tomographic uptake as a prognostic marker before treatment of patients with malignant glioma.

Authors:  Norbert Galldiks; Veronika Dunkl; Lutz W Kracht; Stefan Vollmar; Andreas H Jacobs; Gereon R Fink; Michael Schroeter
Journal:  Mol Imaging       Date:  2012 Nov-Dec       Impact factor: 4.488

10.  Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities.

Authors:  Diem Kieu Thi Tran; Randy L Jensen
Journal:  Surg Neurol Int       Date:  2013-04-17
View more
  6 in total

Review 1.  The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI.

Authors:  Giulia Santo; Riccardo Laudicella; Flavia Linguanti; Anna Giulia Nappi; Elisabetta Abenavoli; Vittoria Vergura; Giuseppe Rubini; Roberto Sciagrà; Gaspare Arnone; Orazio Schillaci; Fabio Minutoli; Sergio Baldari; Natale Quartuccio; Sotirios Bisdas
Journal:  Diagnostics (Basel)       Date:  2022-03-29

2.  The performance of 11C-Methionine PET in the differential diagnosis of glioma recurrence.

Authors:  Weilin Xu; Liansheng Gao; Anwen Shao; Jingwei Zheng; Jianmin Zhang
Journal:  Oncotarget       Date:  2017-07-05

Review 3.  Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas.

Authors:  Kamalakannan Palanichamy; Arnab Chakravarti
Journal:  Front Oncol       Date:  2017-11-01       Impact factor: 6.244

4.  Optimization of diagnostic performance for differentiation of recurrence from radiation necrosis in patients with metastatic brain tumors using tumor volume-corrected 11C-methionine uptake.

Authors:  Tae-Young Jung; In-Young Kim; Sa-Hoe Lim; Ki Seong Park; Dong-Yeon Kim; Shin Jung; Kyung-Sub Moon; Woo-Youl Jang; Sae-Ryung Kang; Sang-Geon Cho; Jung-Joon Min; Hee-Seung Bom; Seong Young Kwon
Journal:  EJNMMI Res       Date:  2017-05-23       Impact factor: 3.138

5.  Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.

Authors:  Hiroyuki Tatekawa; Hiroyuki Uetani; Akifumi Hagiwara; Shadfar Bahri; Catalina Raymond; Albert Lai; Timothy F Cloughesy; Phioanh L Nghiemphu; Linda M Liau; Whitney B Pope; Noriko Salamon; Benjamin M Ellingson
Journal:  Ann Nucl Med       Date:  2021-06-14       Impact factor: 2.668

6.  Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis.

Authors:  Meng Cui; Rocío Isabel Zorrilla-Veloz; Jian Hu; Bing Guan; Xiaodong Ma
Journal:  Front Neurol       Date:  2021-05-20       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.